for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BRIEF-Eli Lilly Receives U.S. FDA Approval For Retevmo

May 8 (Reuters) - Eli Lilly and Co:

* LILLY RECEIVES U.S. FDA APPROVAL FOR RETEVMO™ (SELPERCATINIB), THE FIRST THERAPY SPECIFICALLY FOR PATIENTS WITH ADVANCED RET-DRIVEN LUNG AND THYROID CANCERS

* RETEVMO IS EXPECTED TO BE AVAILABLE FROM SPECIALTY PHARMACIES WITHIN ONE WEEK. Source text for Eikon: Further company coverage:

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up